Abstract:Histone deacetylase 11 (HDAC11) is the lone class IV HDAC whose biological function is largely unexplored. Previously, we demonstrated that deletion of HDAC11 in vivo stimulates brown adipose tissue (BAT) formation and beiging of white adipose tissue (WAT) via a genomic mechanism dependent on physical association with BRD2, a bromodomain and extraterminal (BET) acetyl‐histone binding protein in brown adipocytes. Here, we hypothesize that HDAC11 inactivation primes the heart for protection from pathological remodeling consequent to diet‐induced obesity (DIO) via modulation of adipose tissue transcriptome and secretome (Figure 1). Gene expression analysis showed that selective pharmacologic inhibition of HDAC11 promotes brown adipocyte formation and Ucp1 expression in vitro and in vivo. HDAC11‐deficient mice, in response to high‐fat feeding, exhibit attenuated obesity, insulin resistance, and hepatic steatosis, concomitant with increased levels of the circulating cardioprotective hormone adiponectin. Using histological analysis, atomic force microscopy and quantitative mass spectrometry, we demonstrate that adipose tissue lacking HDAC11 is protected from pathologic remodeling as a consequence of chronic high caloric diet administration. At the level of the heart, we demonstrate for the very first time that HDAC11 functions as a negative regulator of physiological hypertrophy. HDAC11‐deficient hearts exhibit attenuated hypertrophic gene expression after chronic high‐fat feeding. HDAC11 loss also protects cardiomyocytes from pathological hypertrophy and fetal gene activation induced by high fat serum. Using orthogonal click chemistry, fluorescence correlation spectroscopy and super‐resolution microscopy, we establish for the first time that HDAC11 exerts its non‐genomic action by modifying fatty acylation of a cytosolic scaffolding protein, AKAP12 (a.k.a. gravin) and regulation of β‐adrenergic receptor signaling (Figure 2). These findings outline a novel and highly druggable pathway for the regulation of cardiometabolic disease at the level of adipose tissue and the heart, and suggest a potential for HDAC11‐selective inhibitors for the treatment of obesity and cardiometabolic disease.Support or Funding InformationThis work was supported by NIH (HL116848, HL127240, HL147558, DK119594) and the American Heart Association (16SFRN31400013) to T.A.M. R.A.B. (FRN‐216927) and J.L.M. (FRN‐395620) received funding from the Canadian Institutes of Health Research.Proposed model for HDAC11‐mediated cross‐talk between adipose tissue and the heart in cardiometabolic disease.Figure 1Schematic of the mechanism for HDAC11 modulation of AKAP12‐mediated βAR signaling.Figure 2

Deacetylase‐dependent and ‐independent role of HDAC3 in cardiomyopathy

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Mouse SIRT3 Attenuates Hypertrophy-Related Lipid Accumulation in the Heart Through the Deacetylation of LCAD.

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Abstract 19689: Kdm3a Protects Myocardium from Ischemia/reperfusion Injury Through Targeting Akt-dependent Signaling Pathways

Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure

Elucidation of the Role of a Lysine Demyristoylase in Adipose Tissue‐myocardium Crosstalk in Cardiometabolic Disease

Abstract 23931: Selective Inhibition of Hdac3 Prevents Diabetic Cardiomyopathy in Ove26 Mice Via Mir-200a-mediated Nrf2 Activation

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Abstract 20514: Cardiac-Specific Overexpression of Histone Deacetylase 4 Promotes Cardiac Dysfunction and Enhances Cardiac Remodeling

Rg3 Regulates Myocardial Pyruvate Metabolism Via P300-mediated Dihydrolipoamide Dehydrogenase 2-Hydroxyisobutyrylation in TAC-induced Cardiac Hypertrophy

Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium.

Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction

Identify Tcea3 as a novel anti-cardiomyocyte hypertrophy gene involved in fatty acid oxidation and oxidative stress

CaMKII Exacerbates Heart Failure Progression by Activating Class I HDACs.

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Loss of KDM5B ameliorates pathological cardiac fibrosis and dysfunction by epigenetically enhancing ATF3 expression

Endocardial HDAC3 is required for myocardial trabeculation

Regulation of Acetylation Restores Proteolytic Function of Diseased Myocardium in Mouse and Human

The Role of HDAC3 and Its Inhibitors in Regulation of Oxidative Stress and Chronic Diseases

Histone Deacetylase 3 is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow